Your browser doesn't support javascript.
loading
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy.
Loso, Jefferson; Lund, Natalie; Avanesov, Maxim; Muschol, Nicole; Lezius, Susanne; Cordts, Kathrin; Schwedhelm, Edzard; Patten, Monica.
Afiliação
  • Loso J; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Lund N; Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
  • Avanesov M; Department of Diagnostic and Interventional Radiology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • Muschol N; Department of Pediatrics, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • Lezius S; Department of Medical Biometry and Epidemiology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • Cordts K; Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • Schwedhelm E; DZHK (German Center for Cardiovascular Research e.V.), Hamburg, Germany.
  • Patten M; Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
Front Cardiovasc Med ; 5: 108, 2018.
Article em En | MEDLINE | ID: mdl-30159316
ABSTRACT

Background:

Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease.

Methods:

Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography-mass spectrometry.

Results:

Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9 8.0 ± 3.4 vs. 5.0 ± 2.4 µg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 µmol/l) compared to patients without (0.57 ± 0.10 µmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 µmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045).

Conclusion:

Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article